|
David A. Stamler M.D. has been our senior vice president and chief medical officer since July 2008. From 2005 to 2008 Dr. Stamler was chief scientific officer and head of drug development for Prestwick Pharmaceuticals Inc. where he led clinical and pre-clinical development activities for a portfolio of CNS compounds. Prior to Prestwick from 1997 to 2005 Dr. Stamler held several positions with Fujisawa Pharmaceutical Company the most recent of which was senior global project leader for CNS Diseases and vice president of research and development Medical Sciences for Fujisawa’s U.S. subsidiary Fujisawa Healthcare Inc. From 1993 to 1997 Dr. Stamler held several positions with Abbott Laboratories the most recent of which was director of clinical research Pharmaceutical Products for the International Division. Dr. Stamler received B.A. and M.D. degrees from the University of Chicago. He completed his residency in internal medicine at Temple University Hospital as well as fellowships in infectious diseases and clinical microbiology at the University of Pennsylvania. He is board certified in internal medicine. Dr. Stamler is a founding member of the American Society of Experimental NeuroTherapeutics (ASENT) and a member of the American Academy of Neurology and the American College of Physicians. He has authored publications in peer-reviewed scientific journals for CNS gastrointestinal respiratory and inflammatory diseases. | 